Corrigendum to “Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study” [Vaccine: X 11 (2022) 100189]
Titel:
Corrigendum to “Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study” [Vaccine: X 11 (2022) 100189]
Auteur:
Sáez-Llorens, Xavier Lanata, Claudio Aranguren, Elaine Celis, Carlos R. Cornejo, Rubelio DeAntonio, Rodrigo Ecker, Lucie Garrido, Diegi Gil, Ana I. Gonzales, Marina Hess-Holtz, Morgan Leroux-Roels, Geert Junker, Helga Kays, Sarah-Katharina Koch, Sven D. Lazzaro, Sandra Mann, Philipp Quintini, Gianluca Srivastava, Barkha Vahrenhorst, Dominik von Eisenhart-Rothe, Philipp Wolz, Olaf-Oliver Oostvogels, Lidia